Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia

Haematologica

Volumn 98, Issue 4, 2013, Pages 591-596

  Pollyea, Daniel A ^a,c   Zehnder, James ^a   Coutre, Steve ^a   Gotlib, Jason R ^a   Gallegos, Leonel ^a   Abdel Wahab, Omar ^b   Greenberg, Peter ^a   Zhang, Bing ^a   Liedtke, Michaela ^a   Berube, Caroline ^a   Levine, Ross ^b   Mitchell, Beverly S ^a   Medeiros, Bruno C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; GROWTH FACTOR; HYDROXYUREA; LENALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLEEDING; BLOOD CELL COUNT; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; COUGHING; DIARRHEA; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL DISEASE; GENE EXPRESSION PROFILING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN TISSUE; HYPONATREMIA; INJECTION SITE REACTION; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PRURITUS; RASH; SEPSIS; TREATMENT OUTCOME; VOMITING;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MUTATION; NAUSEA; NUCLEAR PROTEINS; PROGNOSIS; REMISSION INDUCTION; THALIDOMIDE; TREATMENT OUTCOME; VOMITING;

EID: 84875665885     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.076414     Document Type: Article

References (23)

1. Tefferi A, Letendre L. Going beyond 7 + 3 regimens in the treatment of adult acute myeloid leukemia. J Clin Oncol. 2012;30 (20):242558.
2. Pollyea DA, Kohrt HE, Medeiros BC. Acute myeloid leukaemia in the elderly: a review. Br J Haematol. 2011;152(5):524-42.
3. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349(21): 2042-54.
4. Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Germing U, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28(4):562-9.
5. Sekeres MA, List AF, Cuthbertson D, Paquette R, Ganetzky R, Latham D, et al. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol. 2010;28(13):2253-8.
6. Lancet JE, Komrokji RS, Yu D, Advani AS, Searles T, Sekeres MA, et al. A phase 1 study of sequential idarubicin + cytarabine, followed by lenalidomide, in patients with previously untreated acute myeloid leukemia (AML). Blood (ASH Annual Meeting Abstracts) 2011;118: Abstract 2600.
7. Sorror ML, Giralt S, Sandmaier BM, De Lima M, Shahjahan M, Maloney DG, et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood. 2007;110(13): 4606-13.
8. Pollyea DA, Kohrt HE, Gallegos L, Figueroa ME, Abdel-Wahab O, Zhang B, et al. Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. Leukemia. 2012;26(5): 893-901.
9. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Bethesda, MD: National Cancer Institute, 2006. Available at http://ctep.info.nih.gov/reporting/ctc.html
10. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-74.
11. Medeiros BC, Othus M, Fang M, Roulston D, Appelbaum FR. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood. 2010;116(13):2224-8.
12. Medeiros BC, Kohrt HE, Gotlib J, Coutre SE, Zhang B, Arber DA, et al. Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia. Am J Hematol. 2012;87(1):45-50.
13. Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol. 2011;29(33):4417-23.
14. Juliusson G, Antunovic P, Derolf A. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113(18):4179-87.
15. Kantarjian H, O'Brien S. Questions regarding frontline therapy of acute myeloid leukemia. Cancer. 2010;116(21):4896-901.
16. Burnett AK, Milligan D, Goldstone A, Prentice A, McMullin MF, Dennis M, et al. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br J Haematol. 2009;145(3): 318-32.
17. Fehniger TA, Uy GL, Trinkaus K, Nelson AD, Demland J, Abboud CN, et al. A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood. 2011;117(6): 1828-33.
18. Scherman E, Malak S, Perot C, Gorin NC, Rubio MT, Isnard F. Interest of the association azacitidine-lenalidomide as frontline therapy in high-risk myelodysplasia or acute myeloid leukemia with complex karyotype. Leukemia. 2012;26(4):822-4.
19. Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA. 2010;107(16):7473-8.
20. Sekeres MA, Gundacker H, Lancet J, Advani A, Petersdorf S, Liesveld J, et al. A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605. Blood. 2011;118(3): 523-8.
21. Marcucci G, Haferlach T, Döhner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol. 2011;29(5):475-86.
22. Röllig C, Bornhäuser M, Thiede C, Taube F, Kramer M, Mohr B, et al. Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. J Clin Oncol. 2011;29(20):2758-65.
23. Metzeler KH, Walker A, Geyer S, Garzon R, Klisovic RB, Bloomfield CD, et al. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia. 2012;26(5): 1106-7.